A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cornelia Trimble, MD
Johns Hopkins University
Principal Investigator - Robert L Parker, Jr., MD
Lyndhurst Gynecologic Associates
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
43 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Victoria, Australia
- Facility name not stated
Montreal, Quebec, Canada
- Facility name not stated
Vancouver, Canada
- Facility name not stated
Tallinn, Estonia
- Facility name not stated
Tartu, Estonia
- Facility name not stated
Batumi, Georgia
- Facility name not stated
Tbilisi, Georgia
- Facility name not stated
Bangalore, Karnataka, India
- Facility name not stated
Jaipur, Rajasthan, India
- Facility name not stated
Kolkata, India
- Facility name not stated
New Delhi, India
- Facility name not stated
Pune, India
- Facility name not stated
San Juan, Puerto Rico
- Facility name not stated
Bloemfontein, South Africa
- Facility name not stated
Cape Town, South Africa
- Facility name not stated
Seoul, South Korea
- Facility name not stated
Phoenix, Arizona, United States
- Facility name not stated
Tucson, Arizona, United States
- Facility name not stated
Colton, California, United States
- Facility name not stated
La Mesa, California, United States
- Facility name not stated
Los Angeles, California, United States
- Facility name not stated
Lakewood, Colorado, United States
- Facility name not stated
Boynton Beach, Florida, United States
- Facility name not stated
Fort Lauderdale, Florida, United States
- Facility name not stated
Sarasota, Florida, United States
- Facility name not stated
Baltimore, Maryland, United States
- Facility name not stated
Saginaw, Michigan, United States
- Facility name not stated
Missoula, Montana, United States
- Facility name not stated
Port Jefferson, New York, United States
- Facility name not stated
The Bronx, New York, United States
- Facility name not stated
Raleigh, North Carolina, United States
- Facility name not stated
Winston-Salem, North Carolina, United States
- Facility name not stated
Columbus, Ohio, United States
- Facility name not stated
Oklahoma City, Oklahoma, United States
- Facility name not stated
Eugene, Oregon, United States
- Facility name not stated
Philadelphia, Pennsylvania, United States
- Facility name not stated
Myrtle Beach, South Carolina, United States
- Facility name not stated
Murray, Utah, United States
- Facility name not stated
Pleasant Grove, Utah, United States
- Facility name not stated
Sandy City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2011
- Primary completion
- 31 May 2014
- Completion
- 30 Apr 2015
- Last update posted
- 7 Sept 2018
- Registered enrollment
- 167
- Registry id
- NCT01304524
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.